BIOGEN INC (BIIB) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BIIB • US09062X1037

188.99 USD
-4.82 (-2.49%)
At close: Feb 10, 2026
188.5 USD
-0.49 (-0.26%)
After Hours: 2/10/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to BIIB. BIIB was compared to 523 industry peers in the Biotechnology industry. BIIB has an average financial health and profitability rating. BIIB has a bad growth rate and is valued cheaply. With these ratings, BIIB could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year BIIB was profitable.
  • In the past year BIIB had a positive cash flow from operations.
  • Of the past 5 years BIIB 4 years were profitable.
  • Of the past 5 years BIIB 4 years had a positive operating cash flow.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

  • BIIB has a better Return On Assets (5.51%) than 91.97% of its industry peers.
  • BIIB's Return On Equity of 8.84% is amongst the best of the industry. BIIB outperforms 92.16% of its industry peers.
  • BIIB has a better Return On Invested Capital (9.70%) than 94.46% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 18.27%.
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROIC 9.7%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • The Profit Margin of BIIB (15.98%) is better than 92.35% of its industry peers.
  • BIIB's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 28.50%, BIIB belongs to the top of the industry, outperforming 96.75% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BIIB has declined.
  • BIIB has a better Gross Margin (75.24%) than 83.75% of its industry peers.
  • BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • BIIB has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • BIIB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.44 indicates that BIIB is not in any danger for bankruptcy at the moment.
  • BIIB's Altman-Z score of 3.44 is fine compared to the rest of the industry. BIIB outperforms 69.41% of its industry peers.
  • The Debt to FCF ratio of BIIB is 2.78, which is a good value as it means it would take BIIB, 2.78 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.78, BIIB belongs to the top of the industry, outperforming 92.73% of the companies in the same industry.
  • A Debt/Equity ratio of 0.35 indicates that BIIB is not too dependend on debt financing.
  • BIIB's Debt to Equity ratio of 0.35 is on the low side compared to the rest of the industry. BIIB is outperformed by 68.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Altman-Z 3.44
ROIC/WACC0.8
WACC12.05%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • BIIB has a Current Ratio of 2.72. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • BIIB has a worse Current ratio (2.72) than 68.26% of its industry peers.
  • BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • BIIB has a worse Quick ratio (2.04) than 73.42% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.04
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • BIIB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
  • The earnings per share for BIIB have been decreasing by -14.17% on average. This is quite bad
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%

3.2 Future

  • BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.58% yearly.
  • Based on estimates for the next years, BIIB will show a decrease in Revenue. The Revenue will decrease by -1.22% on average per year.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y1.58%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-1.22%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • BIIB is valuated correctly with a Price/Earnings ratio of 12.36.
  • 97.51% of the companies in the same industry are more expensive than BIIB, based on the Price/Earnings ratio.
  • BIIB is valuated cheaply when we compare the Price/Earnings ratio to 28.03, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 12.42 indicates a correct valuation of BIIB.
  • BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.51% of the companies in the same industry.
  • BIIB is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.97, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.36
Fwd PE 12.42
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 98.09% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BIIB is valued cheaply inside the industry as 97.71% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.25
EV/EBITDA 8.44
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOGEN INC

NASDAQ:BIIB (2/10/2026, 8:00:00 PM)

After market: 188.5 -0.49 (-0.26%)

188.99

-4.82 (-2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner Change-2.81%
Ins Owners0.15%
Ins Owner Change0.83%
Market Cap27.72B
Revenue(TTM)N/A
Net Income(TTM)1.61B
Analysts73.33
Price Target195.32 (3.35%)
Short Float %3.19%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)6.51%
PT rev (3m)11.59%
EPS NQ rev (1m)2%
EPS NQ rev (3m)1.28%
EPS NY rev (1m)0.25%
EPS NY rev (3m)-1.61%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.13%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE 12.36
Fwd PE 12.42
P/S 2.75
P/FCF 12.25
P/OCF 11.3
P/B 1.52
P/tB 11.63
EV/EBITDA 8.44
EPS(TTM)15.29
EY8.09%
EPS(NY)15.21
Fwd EY8.05%
FCF(TTM)15.42
FCFY8.16%
OCF(TTM)16.73
OCFY8.85%
SpS68.62
BVpS124.11
TBVpS16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number206.64
Profitability
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROCE 11.07%
ROIC 9.7%
ROICexc 11.44%
ROICexgc 40.96%
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
FCFM 22.48%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Debt/EBITDA 1.73
Cap/Depr 25.04%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 67.56%
Profit Quality 140.63%
Current Ratio 2.72
Quick Ratio 2.04
Altman-Z 3.44
F-Score5
WACC12.05%
ROIC/WACC0.8
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y1.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-1.22%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%

BIOGEN INC / BIIB FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


How profitable is BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a profitability rating of 6 / 10.


How financially healthy is BIOGEN INC?

The financial health rating of BIOGEN INC (BIIB) is 6 / 10.